参考文献

[1]Cheson BD，Horning SJ，Coiffier B，et al.Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphoma.NCISponsored InternationalWorking Group.JClin Oncol，1999，17（4）：1244.

[2]Juweid ME，Stroobants S，Hoekstra OS，et al.Use of positron emission tomography for response assessment of lymphoma：consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.JClin Oncol，2007，25（5）：571-578.

[3]Cheson BD，Pfistner B，Juweid ME，et al.Revised response criteria for malignant lymphoma.JClin Oncol，2007，25（5）：579-586.

[4]Cheson B，Fisher R，Barrington S，et al.Recommendations for Initial Evaluation，Staging and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma-the Lugano Classification.JClin Oncol，2014，32：3059-3067.

[5]Crocchiolo R，Canevari C，Assanelli A，el al.Pie-transplant18 FDG—PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.Leuk Lymphoma，2008，49（4）：727-733.

[6]Kasamon YL，Wahl RL，Ziessman HA，et al.Phase IIstudy of risk-adapted therapy of newly diagnosed，aggressive non-Hodgkin’s lymphoma based on midtreatment FDG-PET scanning.Biol Blood Marrow Transplant，2009，15（2）：242-248.

[7]Karantanis D，Subramaniam RM，Peller PJ，et al.The value of[（18）F]-fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.Clin Lymphoma，2008，8（2）：94-99.

[8]Enomoto K，Hamada K，Inohara　H，et al.Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET：a comparison with CT and endoscopic findings.Ann Nucl Med，2008，22（4）：261-267.

[9]Barrington SF，Mikhaeel NG，Kostakoglu L，et al.Role of imaging in the staging and response assessment of lymphoma：consensus of the International Conference on Malignant Lymphomas ImagingWorking Group.JClin Oncol，2014，32（27）：3048-3058.

[10]Nols N，Mounier N，Bouazza S，et al.Quantitative and qualitative analysis ofmetabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.Leuk lymphoma，2014，55（4）：773-780.

[11]Yang DH，Ahn JS，Byun BH，et al.Interim PET/CT-based prognosticmodel for the treatment of diffuse large B-cell lymphoma in the post-rituximab era.Ann Hematol，2013，92（4）：471-479.

[12]Pilkington Woll JP，Garcia Vicente AM，Talavera Rubio MP，et al.Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of completemetabolic response.Rev Esp Med Nuel Imagen Mol，2013，32（2）：70-76.

[13]Boellaard R，Delgado-Bolton R，OyenWJ，etal.FDG PET/CT：EANM procedureguidelines for tumour imaging：version 2.0.Eur JNucl Med Mol Imaging，2015，42（2）：328-354.

[14]Barrington SF，Qian W，Somer EJ，etal.Concordance between four European centres of PET reporting criteria designed for use inmulticentre trials in Hodgkin lymphoma.Eur JNucl Med Mol Imaging，2010，37：1824-1833.

[15]Meignan M，GallaminiA，Meignan M，et al.Reporton the first InternationalWorkshop on　interim-PET-scan in Lymphoma.Leuk Lymphoma，2009，50（8）：1257-1260.

（苏丽萍　马 莉）